ArticleAvicenna journal of phytomedicine
Quercetin and
Article in Avicenna journal of phytomedicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Fatty liver disease is characterized by excessive fat accumulation in liver tissue, which can lead to liver failure and cirrhosis. Quercetin (QCT) is a flavonoid known for its antioxidant properties. The therapeutic benefits of Materials and Methods: Thirty mice were randomized in five groups (n=6), including: control, HFD (10 ml/kg), HFD and QCT (50 mg/kg), HFD and CSLE 2% (200 mg/kg), and HFD and QCT (50 mg/kg) in combination with CSLE 2% (200 mg/kg) in the last week. Mice underwent anesthesia on day 43 after a night of fasting, and the levels of hepatic enzymes and biomarkers, antioxidants, and pro-inflammatory factors were measured. Results: Treatment with QCT and CSLE reduced serum levels of alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, cholesterol, triglyceride, low-density lipoprotein cholesterol, very-low-density lipoprotein, total protein, and total bilirubin, and hepatic levels of thiobarbituric acid-reactive substances, while increasing serum high-density lipoprotein cholesterol and the levels of hepatic catalase, superoxide dismutase, and glutathione peroxidase. Conclusion: Treatment with QCT and CSLE may effectively reduce liver steatosis in HFD-fed mice by improving lipid profiles and antioxidant status.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.